With the CMS expected to release the final 2027 Medicare Advantage rate announcement by early April 2026, how will the finalized benchmark rates and risk adjustment phase-ins impact Elevance Health's (ELV) ability to defend its Medicare margins relative to its 12-15% long-term EPS growth target?

Executive Overview As of early April 2026, the Centers for Medicare & Medicaid Services (CMS) is finalizing the 2027 Medicare Advantage (MA) rate announcement. Based on the CY 2027 Advance Notice, the rate environment remains highly constrained, proposing a net average base payment increase of just +0.09% (or +2.54% when factoring in estimated risk score trends). For Elevance Health (ELV), defending Medicare margins in this austere rate environment—compounded by the ongoing phase-in of the v28 risk adjustment model—requires aggressive portfolio repositioning. Despite these structural headwinds, Elevance appears positioned to defend its profitability and has reaffirmed its commitment to its long-term target of 12%-15% adjusted EPS growth beginning in 2027, relying heavily on strategic market exits, benefit recalibration, and diversification through its Carelon services arm. CMS 2027 Rate Environment & Risk Adjustment Dynamics The finalized 2027 MA rates are expected to closely mirror the Advance Notice, presenting a challenging revenue landscape for managed care organizations (MCOs): Anemic Base Rate Growth: The proposed +0.09% base rate increase acts effectively as a real-dollar cut when juxtaposed against underlying medical cost inflation, which has remained elevated across the sector. v28 Risk Adjustment Phase-In: CMS is continuing the multi-year phase-in of the v28 risk adjustment model. This model removes or downgrades thousands of diagnostic codes (particularly related to diabetes, depression, and vascular disease), structurally compressing risk scores. Plans with historically aggressive coding practices face outsized revenue headwinds. Total Payment Impact: Even with an estimated $700M aggregate increase in MA payments system-wide, the +2.54% total expected payment change leaves little room to absorb rising utilization without margin degradation. Elevance Health's Medicare Margin Defense Strategy To protect its enterprise margin target of 5%-6% , Elevance has pivoted from prioritizing membership growth to strictly defending profitability. Deliberate Market Exits: Elevance has actively repositioned its portfolio, executing targeted exits in underperforming MA and commercial risk markets. This intentional shedding of unprofitable covered lives acts as a near-term revenue headwind but is mathematically necessary to stabilize the Medical Loss Ratio (MLR). Benefit Trimming: To offset the gap between the +2.54% effective rate increase and higher medical cost trends, ELV is forced to reduce supplemental benefits (e.g., dental, vision, OTC allowances) and increase out-of-pocket maximums for members. Operational Cost Controls: The company is leveraging administrative cost controls and tighter unit pricing negotiations with providers to insulate its bottom line from the top-line squeeze. Implications for the 12-15% EPS Growth Target Elevance recently established its 2026 adjusted diluted EPS guidance at a baseline of $25.50 (emphasizing the exclusion of $3.75 per share in nonrecurring 2025 items) and reaffirmed its long-term target of at least 12% adjusted EPS growth starting in 2027. The viability of this target in a constrained MA environment rests on several pillars: Carelon as a Growth Engine: With MA premiums pressured, ELV is increasingly reliant on Carelon (its health services and pharmacy benefit management division) to drive unregulated, fee-based earnings growth. Medicaid Margin Recovery: Elevance expects its Medicaid margins to have troughed in 2025/2026 following the post-pandemic redetermination cycle. A stabilization in Medicaid acuity and state-level rate adjustments is critical to offsetting MA weakness. Earnings Mix Shift: By shrinking its exposure to unprofitable MA cohorts, the relative weight of ELV's commercial and specialty care businesses increases, improving overall earnings quality and predictability. Key Risks & Uncertainties While Elevance's strategic pivot appears structurally sound, several variables could disrupt its trajectory: Utilization Spikes: If senior outpatient utilization or inpatient acuity spikes above ELV's pricing assumptions, the tight +2.54% rate environment provides zero margin of error, risking MLR deterioration. Membership Attrition: Aggressive benefit cuts and market exits could trigger higher-than-expected voluntary disenrollment, reducing the scale efficiencies needed to cover fixed administrative costs. Final Rate Deviations: While historically rare, any negative deviation in the final April 2026 CMS announcement from the Advance Notice would require immediate, mid-year operational adjustments to preserve the 12%-15% EPS growth trajectory.

Given the recent volatility in medical loss ratios (MLR) across the managed care sector, what specific evidence of stabilized outpatient utilization or improved CarelonRx pharmacy cost management is required in the upcoming Q1 2026 earnings report to justify Elevance Health's (ELV) current valuation premium?

Executive Overview & Scope Elevance Health (ELV) approaches its Q1 2026 earnings report following a significant baseline reset. Management has explicitly designated 2026 as a "year of execution and repositioning," establishing a conservative adjusted EPS floor of $25.50 (down from the $30.29 achieved in 2025) and a consolidated Benefit Expense Ratio (MLR) target of 90.2% (± 50 basis points). Given the managed care sector's recent MLR volatility—driven by Medicare Advantage (MA) utilization spikes and Medicaid acuity shifts—ELV’s ability to defend its current valuation premium (trading near 14.8x forward earnings) relies heavily on proving that medical cost trends are now predictable and adequately priced. Core Analysis: Required Evidence for Outpatient Utilization Stabilization To justify the valuation and demonstrate that the 2025 outpatient utilization pressures have plateaued, the Q1 2026 print must deliver specific diagnostic evidence: MLR Trajectory and Pricing Alignment: The Q1 MLR must track cleanly toward the 90.2% full-year midpoint. A Q1 MLR printing near or above the upper bound of 90.7% would likely be interpreted as a signal that outpatient pressures (e.g., orthopedic, cardiovascular, and behavioral health volumes) are still accelerating beyond 2026 pricing assumptions. Medicaid Acuity & Margin Troughing: With management forecasting a Medicaid operating margin trough of -1.75% , Q1 must show evidence that state rate updates are beginning to match the higher acuity of the post-redetermination member pool. Investors will look for commentary confirming that Medicaid utilization is not deteriorating further. Medicare Advantage Trend Moderation: Following the elevated medical cost trends that drove the FY2025 MLR up 150 bps to 90.0% (culminating in a Q4 2025 MLR of 93.5% ), ELV must demonstrate that Q1 MA outpatient volumes are normalizing and that 2026 bid pricing is adequately covering current utilization run-rates. Core Analysis: Required Evidence for CarelonRx Pharmacy Cost Management With operating revenue projected to decline in the low single digits due to risk-based membership attrition, Carelon remains ELV's primary growth and margin-defense engine. To validate its cost-management efficacy, the market requires: Part D & IRA Navigation: Clear data showing CarelonRx has successfully managed the pronounced seasonality and liability shifts in Part D benefits associated with the Inflation Reduction Act (IRA) changes implemented in 2025 and 2026. Specialty & GLP-1 Trend Control: Evidence of rigorous utilization management and favorable rebate negotiations for high-cost GLP-1s and specialty therapeutics. This must translate to margin preservation within the Carelon segment, proving that pharmacy costs are not bleeding into the broader MLR. Carelon Margin Discipline: While Carelon saw robust top-line growth in 2025 (e.g., +33% YoY revenue growth in Q3 2025), Q1 2026 must prove margin discipline. Revenue growth must drop to the bottom line to support the consolidated EPS floor and offset the projected low double-digit decline in risk-based membership. Valuation Implications & The "2027 Bridge" ELV’s valuation premium is anchored not on its transitional 2026 earnings, but on management's commitment to return to at least 12% adjusted EPS growth in 2027. If Q1 2026 shows stabilized MLR and effective CarelonRx cost controls, the market will likely treat the $25.50 EPS guidance as a highly credible trough, supporting multiple resilience. Conversely, any structural miss in outpatient utilization will fracture the "2027 bridge" narrative, potentially triggering multiple compression as the market prices in a multi-year margin impairment. Risks, Limitations, and Uncertainties CMS Sanctions: The potential impact of intermediate CMS sanctions on MA-PD plans effective March 31, 2026, is reportedly embedded in the guidance. However, any unexpected enrollment attrition or restricted marketing activity could pressure per-member fixed costs more than anticipated. ACA Premium Elasticity: With average ACA premiums rising roughly 26% in 2026, adverse selection remains a critical risk. If healthier members drop coverage due to affordability constraints, the resulting risk pool could skew older and sicker, inflating MLR later in the year. Analytical Limitations: This analysis relies on management's reaffirmed guidance as of early Q1 2026. Intra-quarter flu/respiratory seasonality and delayed claims processing (IBNR) could obscure true underlying utilization trends in the initial Q1 print.

How do the recent 2026 Medicaid contract awards and the ongoing re-procurement cycle in key states affect Elevance Health's (ELV) membership outlook, and to what extent can the growth in the Carelon health services segment offset potential revenue headwinds from state-level reimbursement tightening?

Executive Overview As of April 2026, Elevance Health (ELV) is navigating a highly dynamic managed care environment characterized by a structural divergence between its core Health Benefits business and its rapidly scaling Carelon health services segment. While recent Medicaid re-procurement wins in key states secure long-term market share, near-term membership attrition and state-level reimbursement rates that trail medical cost trends have forced management to designate 2026 as a "trough year" for Medicaid margins. Carelon's robust double-digit growth is providing a critical financial buffer, though it is only partially offsetting the broader enterprise margin pressures in the immediate term. Medicaid Re-Procurements & Membership Outlook (2026) Elevance's Medicaid membership outlook is a function of both successful state contract retention and the lingering effects of post-pandemic eligibility redeterminations. Contract Awards & Market Share: Elevance has successfully defended and expanded its footprint in critical re-procurement cycles heading into 2026. Notably, in Florida, Elevance was retained as one of the sole holders of market share across all state regions (alongside Centene and Humana), effectively locking out several major competitors. In Nevada, the company secured a new contract starting January 1, 2026, to serve the populous Clark and Washoe counties. These wins solidify Elevance's long-term revenue base and geographic density. Membership Attrition: Despite these contract victories, overall membership has contracted. Elevance ended 2025 with 45.2 million members, representing a decline of approximately -500,000 members year-over-year. This attrition was principally driven by Medicaid eligibility reverifications, which have disproportionately removed healthier, lower-cost members from the risk pool. State-Level Reimbursement Tightening vs. Cost Trends The primary headwind for Elevance's Health Benefits segment in 2026 is the mismatch between state capitation rates and actual medical utilization. Acuity and Utilization Pressures: The members remaining in Elevance's Medicaid plans post-redetermination exhibit persistently higher acuity and utilization rates. Margin Compression: Management has explicitly guided that 2026 will be the low point for Medicaid margins. Elevance projects a Medicaid margin decline of at least -125 bps (1.25 percentage points) in 2026 compared to 2025. Rate Inadequacy: While state rate updates for 2026 are expected to be modestly above historical averages, Elevance's leadership noted they will still trail medical cost trends into 2026. This reimbursement tightening means state payments are currently insufficient to cover the elevated medical costs, directly squeezing the segment's profitability. Carelon’s Growth: The Strategic Offset To counter the structural pressures in the Health Benefits segment, Elevance has aggressively scaled its health services arm, Carelon (comprising CarelonRx and Carelon Services). Revenue Surge: In 2025, Carelon generated $71.7B in total operating revenue, a massive +33% year-over-year increase. CarelonRx revenue climbed to $43.4B ( +21% ), while Carelon Services jumped to $28.3B ( +58% ), heavily aided by the CareBridge acquisition and the expansion of risk-based solutions. Margin Support: Carelon delivered an adjusted operating gain of $3.4B in 2025 ( +10% YoY). CarelonRx maintained a solid 5.6% operating margin, acting as a high-margin counterbalance to the core insurance book. Extent of the Offset: While Carelon's growth is exceptional, it is insufficient to fully offset the Medicaid and Medicare headwinds in the immediate term. Elevance's consolidated operating margin narrowed from 4.5% in 2024 to 3.6% in 2025 due to mounting medical costs. Furthermore, the company's 2026 adjusted diluted EPS guidance of "at least $25.50 " represents a moderation from 2025's $30.29 . This indicates that while Carelon prevents a steeper earnings decline and provides vital cash flow, 2026 remains a transitional, margin-compressed year for the enterprise before anticipated sequential improvements in 2027. Key Risks & Uncertainties State Budget Constraints: If macroeconomic conditions weaken, state governments may further tighten Medicaid budgets, exacerbating the gap between capitation rates and medical cost trends in 2027 and beyond. Carelon Integration & Execution: The rapid +58% revenue growth in Carelon Services relies heavily on integrating acquisitions like CareBridge. Any operational friction could dilute the segment's ability to support enterprise margins. Medical Cost Trend Volatility: The assumption that 2026 is the "trough" for Medicaid margins relies on medical utilization stabilizing. If acuity continues to rise unexpectedly, the projected -125 bps margin contraction could deepen.

Elevance Health Inc. (ELV) Stock Price & AI Analysis

GoAI Score

Sign in to unlock

Valuation

50Fair Value

Sentiment

100Bullish

Risk

100Low Risk

Momentum

42Neutral

Institutional-Grade Intelligence

🏆PRO

Actionable Intelligence

AI-driven stance, execution logic & risk thresholds

Catalyst Roadmap

Event timeline with expected impact & market context

Deep Insights

Fact-checked analysis & score logic breakdown

Financial Statements

Margin Trends

Gross

25.6%▼2.3pp

Revenue after COGS

Operating

4.1%▼1.0pp

After operating expenses

Net

2.8%▼0.5pp

Bottom-line profitability

Gross Margin

Operating Margin

Net Margin

Valuation Snapshot

P/E Ratio

13.7

Price vs earnings

EV/EBITDA

10.5

Enterprise value

FCF Yield

4.1%

Cash generation

Earnings Yield

7.3%

Inverse of P/E

Capital Efficiency

8

GoAI Quality ScoreFair

ROEReturn on Equity

12.9%Fair

ROAReturn on Assets

4.7%Fair

ROICReturn on Invested Capital

6.6%Fair

Financial Health

Current RatioAdequate

1.24

Short-term solvency (>1.5)

Net Debt / EBITDAManageable

2.46x

Debt repayment capacity (<3x)

Income QualityFair

0.76

Cash backs earnings (>1)

Revenue & Profitability

Revenue

Net Income

Net Loss

Income Statement

Metric	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	$199.13B	$176.81B	$171.34B	$156.59B	$138.64B
Gross Profit	$50.90B	$49.24B	$47.01B	$39.95B	$35.99B
Gross Margin	25.6%	27.9%	27.4%	25.5%	26.0%
Operating Income	$8.11B	$8.89B	$8.74B	$8.45B	$8.95B
Net Income	$5.66B	$5.98B	$5.99B	$5.89B	$6.10B
Net Margin	2.8%	3.4%	3.5%	3.8%	4.4%
EPS	$25.18	$25.81	$25.38	$24.56	$25.25

Average Price Target

$382.64▲ 22.7% Upside

Past 12 Months

12 Month Forecast

Based on 50 Wall Street analysts offering 12 month price targets for Elevance Health Inc., the average price target is $382.64, with a high forecast of $425.00 and a low forecast of $332.00. The average price target represents a 22.7% increase from the current price of $311.83.

Highest

$425.00

Average

$382.64

Lowest

$332.00

Rating Distribution

Strong Buy

0

0%

Buy

26

70%

Hold

11

30%

Sell

0

0%

Strong Sell

0

0%

Recent Analyst Ratings

FirmActionRatingDate

Mizuho● Maintain

Outperform

2026-03-11

Truist Securities● Maintain

Buy

2026-02-02

JP Morgan● Maintain

Overweight

2026-02-02

Barclays● Maintain

Overweight

2026-01-30

Wells Fargo● Maintain

Overweight

2026-01-30

Guggenheim● Maintain

Buy

2026-01-29

Guggenheim● Maintain

Buy

2026-01-22

Wolfe Research▲ Upgrade

Peer Perform→Outperform

2026-01-08

Wells Fargo● Maintain

Overweight

2026-01-07

Barclays● Maintain

Overweight

2026-01-05

Earnings History & Surprises

BEAT RATE

89%

Last 18 quarters

AVG SURPRISE

+3.3%

EPS vs Estimate

BEATS / MISSES

16/2

Last 18 quarters

LATEST EPS

$3.33

Q1 '26

QUARTERLY EPS TREND

Estimated

Beat

Miss

QUARTERLY DETAIL

Q1 '26

+7.4%

$3.33 vs $3.10

Q4 '25

+22.3%

$6.03 vs $4.93

Q3 '25

-0.8%

$8.84 vs $8.91

Q2 '25

+4.9%

$11.97 vs $11.41

Q1 '25

+1.1%

$3.84 vs $3.80

Q4 '24

-13.4%

$8.37 vs $9.66

Q3 '24

+1.1%

$10.12 vs $10.01

Q2 '24

+1.0%

$10.64 vs $10.53

Q1 '24

+1.3%

$5.62 vs $5.55

Q4 '23

+6.4%

$8.99 vs $8.45

Q3 '23

+2.7%

$9.04 vs $8.80

Q2 '23

+2.2%

$9.46 vs $9.26

Investor Q&A

Top questions investors are asking about Elevance Health Inc.

3 Questions

Ask GoAI anything about Elevance Health Inc.

Latest News

No news available